diabetes-congress-cancer-summit-2019-scientifictracks

6 / 10

Volume: 08 Research & Reviews: Journal of Medical & Health Sciences
Page 17
Notes:
Diabetes Congress & Cancer summit 2019
December 04-05, 2019
conferenceseries.com
December 04-05, 2019 | Tokyo, Japan
Asia Pacific Conference on
Diabetes Oncology
Cintia do Couto Mascarenhas et al., RRJMHS 2019, ISSN: 2319-9865
Pre, during and post colorectal cancer (CRC) screening age and differences in pathology and
mutational status among patients
Cintia do Couto Mascarenhas, Gustavo Fernandes1, Allan A. Lima Pereira1, Gabriella T. P. Braga2, Cintia do Couto 2 Mascarenhas, Brenda Gumz1,
Marcela Crosara1, Daniel Girardi1, Adriana Barrichello1 and Heinrich Seidler 2
1Syrian Lebanese Hospital, Brasilia, Brazil
2Catholic University, Brasilia, Brazil
Even though the screening protocols are e cient and widely recommended in reducing mortality for colon-rectum cancer
the populations from di erent age groups can have distinct pathological and molecular pro les what can in uence by
screening and polyp resection, especially in older ages. A retrospective analysis was performed in tumors from stage IV CRC
patients from a central pathology laboratory in Brazil that is a reference for mutational pro ling countrywide. e study
population was classi ed as pre-screening (PrSA; <45yo), screening(SA; 45-75yo) and post-screening age (PoSA; >75yo).
Every tumor has been centrally reviewed by the pathologist. Groups were compared regarding clinicopathologic features and
presence of RAS and BRAF mutations. Was included 1244 pts (164 PrSA, 919 SA and 161 PoSA) and have no signi cant
di erence among groups regarding sidedness (p= 0.68) and KRAS mutations (p=.0.97). Stage IV at diagnose (p =.001), presence
of signet-ring cell component (p< .001) along with poorly di erentiated tumors (p= .006) were most found on young patients,
while BRAF and NRAS mutations where signi cantly more common among PosSA (table). PosSA and PreSA CRCs seem to
present a distinct pro le from SA populations, including molecular and pathologic di erences what can impact the frequency
of screening tests among di erent age groups.
Biography
Cintia do Couto Mascarenhas has completed her PhD at the age of 29 years from Faculty of Medicine - University of Campinas and postdoctoral studies from
Catholic University of Brasília. She was a coordenator of clinical research center at Hematology and Hemoterapy Center at UNICAMP. She was a professor
at Catholic University of Brasília since 2013 until 2019 july. Currently she is a CEO of 1Health Services a early startup, Ad hoc at Department of Science and
Technology of the Brazilian Ministry of Health and also making her second undergraduate in Medicine.